Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

Price is unknown


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. The company was founded in 1986 and is headquartered in Dublin, Ireland. Shire plc is a subsidiary of Takeda Pharmaceutical Company Limited.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Equity (BVPS) 5.25
6.77
7.14
11.11
16.12
32.94
35.94
growth rate 29.0% 5.5% 55.6% 45.1% 104.3% 9.1%
Earnings BIT 1,698.70
2,231.70
2,217.30
3,078.60
4,165.00
4,047.50
growth rate 31.4% -0.7% 38.8% 35.3% -2.8%
Avg.PE 256.88
148.79
8.85
24.90
growth rate -42.1% -94.1% 181.4%
ROA 3.78
11.50
11.75
14.70
10.88
8.51
31.02
8.62
0.78
6.34
growth rate 204.2% 2.2% 25.1% -26.0% -21.8% 264.5% -72.2% -91.0% 712.8%
ROE 12.36
30.63
26.95
30.69
21.31
14.50
48.55
14.10
1.69
13.12
growth rate 147.8% -12.0% 13.9% -30.6% -32.0% 234.8% -71.0% -88.0% 676.3%
ROIC 9.48
18.97
18.53
20.00
16.84
13.53
43.38
12.76
2.83
10.32
growth rate 100.1% -2.3% 7.9% -15.8% -19.7% 220.6% -70.6% -77.8% 264.7%
Cur. Ratio 1.27
1.54
1.45
0.87
1.95
2.37
1.72
0.61
0.97
0.97
growth rate 21.3% -5.8% -40.0% 124.1% 21.5% -27.4% -64.5% 59.0% 0.0%
Quick Ratio 0.74
1.07
0.96
0.58
1.40
1.77
1.33
0.36
0.41
0.44
growth rate 44.6% -10.3% -39.6% 141.4% 26.4% -24.9% -72.9% 13.9% 7.3%
Leverage 3.03
2.41
2.20
2.00
1.92
1.55
1.57
1.69
2.32
1.87
growth rate -20.5% -8.7% -9.1% -4.0% -19.3% 1.3% 7.6% 37.3% -19.4%
Balance Sheet Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Acct.Receivable 976.00
1,153.10
1,170.40
1,293.00
3,083.30
3,352.60
3,071.60
growth rate 18.2% 1.5% 10.5% 138.5% 8.7% -8.4%
Acct.Payable 208.00
202.60
247.70
441.40
911.90
914.60
4,800.70
growth rate -2.6% 22.3% 78.2% 106.6% 0.3% 424.9%
Cur.Assets 3,212.00
4,288.30
5,183.10
2,255.50
7,539.50
7,608.40
8,525.70
growth rate 33.5% 20.9% -56.5% 234.3% 0.9% 12.1%
Total Assets 7,317.00
8,323.00
13,632.10
16,609.80
67,035.40
67,756.90
63,879.30
growth rate 13.8% 63.8% 21.8% 303.6% 1.1% -5.7%
Cash 1,482.00
2,239.40
2,982.40
135.50
528.80
472.40
924.60
growth rate 51.1% 33.2% -95.5% 290.3% -10.7% 95.7%
Inventory 437.00
455.30
544.80
635.40
3,562.30
3,291.50
3,497.50
growth rate 4.2% 19.7% 16.6% 460.6% -7.6% 6.3%
Cur.Liabilities 1,646.00
1,807.90
3,021.90
3,706.10
7,743.30
7,882.00
8,487.10
growth rate 9.8% 67.2% 22.6% 108.9% 1.8% 7.7%
Liabilities 3,508.00
2,957.00
4,969.20
6,780.70
38,087.40
31,580.50
26,123.30
growth rate -15.7% 68.1% 36.5% 461.7% -17.1% -17.3%
LT Debt 1,100.00
70.00
70.00
69.90
19,552.60
16,410.70
10,749.90
growth rate -93.6% 0.0% -0.1% 27,872.3% -16.1% -34.5%
Equity 5,366.00
8,662.90
9,829.10
28,948.00
36,176.40
37,756.00
growth rate 61.4% 13.5% 194.5% 25.0% 4.4%
Common Shares 545.00
548.00
562.00
595.00
594.00
590.00
58.70
58.90
81.30
81.60
82.20
growth rate 0.6% 2.6% 5.9% -0.2% -0.7% -90.1% 0.3% 38.0% 0.4% 0.7%
Cash Flow Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Capital Expenditures 150.00
157.00
114.70
114.70
648.70
798.80
787.00
growth rate 4.7% -26.9% 0.0% 465.6% 23.1% -1.5%
Cash Dividends 96.40
121.20
134.40
171.30
281.30
327.50
growth rate 25.7% 10.9% 27.5% 64.2% 16.4%
Cash From OA 1,383.00
1,463.00
4,228.40
2,337.00
2,658.90
4,256.70
4,610.10
growth rate 5.8% 189.0% -44.7% 13.8% 60.1% 8.3%
FCF per Share 1.35
2.00
1.79
3.68
6.82
2.63
3.36
growth rate 48.2% -10.5% 105.6% 85.3% -61.4% 27.8%
Sale Purchase of Stock 17.20
17.40
16.60
169.20
134.10
growth rate 1.2% -4.6% 919.3% -20.7%
FCF 539.00
366.00
626.00
874.00
1,189.00
1,306.00
4,151.00
2,222.00
2,010.00
3,458.00
3,823.10
growth rate -32.1% 71.0% 39.6% 36.0% 9.8% 217.8% -46.5% -9.5% 72.0% 10.6%
Income Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Sales 4,527.00
4,934.30
6,022.10
6,416.70
11,396.60
15,160.60
15,490.00
growth rate 9.0% 22.1% 6.6% 77.6% 33.0% 2.2%
Op.Income 806.00
1,698.70
2,231.70
2,217.30
3,078.60
4,165.00
4,047.50
growth rate 110.8% 31.4% -0.7% 38.8% 35.3% -2.8%
IBT 1,697.50
3,338.90
1,383.60
477.40
1,895.90
2,758.30
growth rate 96.7% -58.6% -65.5% 297.1% 45.5%
Net Income 806.00
665.10
3,405.50
1,303.40
327.40
4,271.50
2,327.40
growth rate -17.5% 412.0% -61.7% -74.9% 1,204.7% -45.5%
EPS 0.28
0.90
1.05
1.50
1.30
1.18
5.76
2.20
0.42
4.68
growth rate 221.4% 16.7% 42.9% -13.3% -9.2% 388.1% -61.8% -80.9% 1,014.3%
Gross Profit 3,942.00
4,263.50
5,134.70
5,478.80
8,698.10
11,207.60
10,948.80
growth rate 8.2% 20.4% 6.7% 58.8% 28.9% -2.3%
R&D 913.50
877.20
920.30
1,430.90
1,743.30
1,695.30
growth rate -4.0% 4.9% 55.5% 21.8% -2.8%

Quarterly Statements

Item Name Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Earnings BIT 1,150.60
972.80
1,019.80
1,037.90
1,008.10
growth rate -15.5% 4.8% 1.8% -2.9%
Balance Sheet Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Acct.Receivable 3,352.60
3,289.60
3,061.10
3,263.00
3,071.60
growth rate -1.9% -7.0% 6.6% -5.9%
Acct.Payable 914.60
3,939.00
3,888.50
4,025.10
4,800.70
growth rate 330.7% -1.3% 3.5% 19.3%
Cur.Assets 7,608.40
7,915.00
9,788.40
7,799.30
8,525.70
growth rate 4.0% 23.7% -20.3% 9.3%
Total Assets 67,756.90
67,868.80
66,222.10
63,765.90
63,879.30
growth rate 0.2% -2.4% -3.7% 0.2%
Cash 472.40
317.70
259.70
193.20
924.60
growth rate -32.8% -18.3% -25.6% 378.6%
Inventory 3,291.50
3,340.80
3,353.30
3,458.70
3,497.50
growth rate 1.5% 0.4% 3.1% 1.1%
Cur.Liabilities 7,882.00
6,944.60
6,307.30
8,511.60
8,487.10
growth rate -11.9% -9.2% 35.0% -0.3%
Liabilities 31,580.50
30,468.80
29,461.70
26,475.70
26,123.30
growth rate -3.5% -3.3% -10.1% -1.3%
LT Debt 16,410.70
16,391.80
16,383.20
10,740.70
10,749.90
growth rate -0.1% -0.1% -34.4% 0.1%
Equity 36,176.40
37,400.00
36,760.40
37,290.20
37,756.00
growth rate 3.4% -1.7% 1.4% 1.3%
Common Shares 81.60
81.70
81.90
81.90
82.20
growth rate 0.1% 0.2% 0.0% 0.4%
Cash Flow Statement Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Capital Expenditures 233.30
177.80
183.50
203.30
222.40
growth rate -23.8% 3.2% 10.8% 9.4%
Cash Dividends 46.60
276.60
276.60
50.90
50.90
growth rate 493.6% 0.0% -81.6% 0.0%
Cash From OA 1,519.60
1,010.30
939.60
857.60
1,802.60
growth rate -33.5% -7.0% -8.7% 110.2%
Sale Purchase of Stock 41.90
40.50
growth rate -3.3%
FCF 1,286.30
832.50
756.10
654.30
1,580.20
growth rate -35.3% -9.2% -13.5% 141.5%
Income Statement Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Sales 4,144.90
3,765.70
3,919.50
3,871.70
3,933.10
growth rate -9.2% 4.1% -1.2% 1.6%
Op.Income 1,150.60
972.80
1,019.80
1,037.90
1,008.10
growth rate -15.5% 4.8% 1.8% -2.9%
IBT 703.80
593.90
739.90
740.50
684.00
growth rate -15.6% 24.6% 0.1% -7.6%
Net Income 3,105.40
550.60
615.50
537.20
624.10
growth rate -82.3% 11.8% -12.7% 16.2%
Gross Profit 2,940.50
2,666.80
2,811.20
2,714.10
2,749.30
growth rate -9.3% 5.4% -3.5% 1.3%
R&D 418.80
405.20
427.60
407.20
455.30
growth rate -3.3% 5.5% -4.8% 11.8%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

A (84.01)

YOY Growth Grade:

C (59.95)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 24.90 24.90 11.75
EPS / Growth 12.5% 2.53 3.6%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 33.5%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 3.6% 16.5% 16.5%
Future PE 7.12 23.22 23.22
Future EPS 3.59 11.66 11.66
Value Price
MOS %
6.32
66.95
66.95
MOS Price 3.16 33.47 33.47
IRT

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.